56 results
8-K
EX-99.1
ANAB
AnaptysBio Inc
10 Oct 23
Regulation FD Disclosure
9:01am
, that is being developed for the treatment of GPP. GPP is a rare, chronic, systemic autoinflammatory disease that is potentially life-threatening, if left
8-K
EX-99.2
i2025aqmbr5xqvyvdpv
8 Nov 22
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
4:08pm
8-K
EX-99.1
w3f 07rztxf9
12 Sep 22
Entry into a Material Definitive Agreement
7:32am
8-K
EX-99.1
gooudn dc9h6
31 Aug 22
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
4:19pm
8-K
EX-99.1
bm3nwpvl50jmqvpiwc4
4 Oct 21
AnaptysBio Presents Updated Data From Imsidolimab
9:00am
8-K
EX-99.1
5kmiwkkx 0s9b087m3
25 Feb 21
AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates
4:09pm
8-K
EX-99.1
ro0x4atbdx
4 Nov 20
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates
4:02pm
8-K
EX-99
ec1bbn1vueqj6jt
13 Oct 20
Regulation FD Disclosure
9:05am